Compare Ascendis Pharma A/S (ASND) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Marathon Petroleum Corp — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while Marathon Petroleum Corp trades at $295 (market cap $82.83B). The key difference: Marathon Petroleum Corp is far larger — about 4.7× Ascendis Pharma A/S's market cap, and Marathon Petroleum Corp pays a 1.38% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MPC | |
|---|---|---|
Market Cap | $17.74B | $82.83B |
Sector | Health | Energy |
52-Week High | $277.18 | $283.74 |
52-Week Low | $163.32 | $158.59 |
Enterprise Value | $18.11B | $115.01B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Marathon Petroleum (MPC) trades at $283.74, up 0.16% with a bullish technical outlook supported by moving averages. The stock shows strong profitability with 27.92% ROE and attractive valuation metrics including P/E of 18.68 and P/S of 0.63. Recent earnings beat expectations in Q4 2025 and Q1 2026, while refining capacity constraints and Middle East tensions provide tailwinds for the energy sector.
MPC presents a compelling value opportunity with solid fundamentals and positive analyst sentiment, though investors face risks from volatile oil prices, regulatory scrutiny over pricing practices, and declining revenue trends. The stock trades near analyst consensus target of $278.38 with 76% buy ratings supporting upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
